Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822181 · ClinicalTrials.gov registry record · Phase 3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
A Phase 3 study of Non-alcoholic Steatohepatitis, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 1,205
- Enrollment target
- 20
- Study locations
NCT04822181 is a Phase 3 study of Non-alcoholic Steatohepatitis that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,205 participants, above the 196-participant average among 12 other Non-alcoholic Steatohepatitis trials with a reported enrollment target (515% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04822181, a Phase 3 study of Non-alcoholic Steatohepatitis, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,205 participants
- Enrollment target
- 20
- Study locations
Study Summary
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (20)
California
- Gastroenterology & Liver Institute - Escondido
- Shang Wu M.D. Inc. - Hacienda Heights
- Scripps Whittier Diabetes Inst - La Jolla
- UCSD NAFLD Research Center - La Jolla
- OM Research LLC - Lancaster
- Digestive Hlth Res of SoCa - Long Beach
- OM Research LLC - Oxnard
- Cedars-Sinai Medical Center - Pasadena
- Pasedena Liver Center - Pasadena
- Inland Empire Clin Trials LLC - Rialto
- UC Davis Hlth -Midtwn Ambu Cen - Sacramento
- University of California, San Francisco - San Francisco
Arizona
- The Institute for Liver Health - Chandler
- Inst-Liver Hlth dba AZ Liver H - Peoria
- Inst. Liver H II dba AZ Liver H - Tucson
- Del Sol Research Management, LLC - Tucson
Arkansas
- ARcare Center for Clinical Research - Jonesboro
- ARcare Center for Clinical Research - Little Rock
- Arkansas Diagnostic Center, PA - Little Rock
Alabama
- North AL Health Res, LLC - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,205 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2029-04-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04822181
The ClinicalTrials.gov registry entry for NCT04822181 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,205 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 12 other Non-alcoholic Steatohepatitis trials with a reported enrollment target (515% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04822181 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04822181 about?
NCT04822181 is a clinical study titled "Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)". Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Particip...
What is the current status of trial NCT04822181?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,205 participants. The study started on 2021-04-01. Estimated completion is 2029-04-25.
What conditions does trial NCT04822181 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis.
What interventions are being tested in trial NCT04822181?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT04822181?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04822181 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
RECRUITING
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
The Olmsted NAFLD Epidemiology Study (TONES)
RECRUITING · NA
-
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
COMPLETED · Phase 2
-
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.